Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP
Corbus Pharmaceuticals — Investor Presentation (January 2018)
56 slides from Corbus Pharmaceuticals's investor presentation, Jan 8, 2018
Slide 1: Developing Breakthrough Therapies for Rare Inflammatory and Fibrotic Diseases
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain forward-looking statements, including those relating to the Company’s product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, bus
Slide 3: Overview
x Overview Focus on rare, chronic, serious inflammatory and fibrotic diseases tt Advancing 4 late-stage clinical studies Multiple clinical and regulatory First-in-class ey ; Anabasum | oral synthetic . yy endocannabinoid mimetic (v) Positive Phase 2 data in 3 indications Building a commercial Ed pha
Slide 4: Anabasum Pipeline: Multiple Opportunities
vy Anabasum Pipeline: Multiple Opportunities Inflammatory / Fibrotic Diseases Patient Population Phase of Development Orphan Designation Fast Track Status in Rare Autoimmune / Open-Label Extension Nondilutive aetna Highlights ; , Patient dosing Systemic Sclerosis 90,000 Phase 3 Vv V v _ Pen expected
Slide 5: People living with these conditions in the Major Markets
700,000 people living with these 4 conditions in the 7 Major Markets
Slide 6: Top selling drugs in the USA are anti-inflammatory drugs
Top selling drugs in the USA are anti-inflammatory drugs that treat autoimmune diseases! Combined sales of these 4 drugs in the USA in 20162 1) IgeaHub (August 8, 2017) Top 20 Drugs inthe World 2017, httos://izes 2) Gen (March 6, 2017) The Top 15 Best-Selling Drugs of 2016, https://www, i
Slide 7: Drugs approved for these indications
¢ Drugs approved specifically for systemic sclerosis ¢ Drugs approved for treating inflammation in CF ¢ Drugs approved specifically for skin-predominant dermatomyositis
Slide 8: Anabasum Promotes Resolution of Inflammation and Fibrotic Responses
\v Anabasum Promotes Resolution of Inflammation and Fibrotic Responses CORBUS PHARMACEUTICALS Developing Breakthrough Therapies for Rare Inflammatory and Fibrotic Diseases Anabasum: Mechanism of Action
Slide 9: Normal Inflammatory Process vs. Chronic Inflammation
Normal Inflammatory Process vs. Chronic Inflammation Normal Inflammation Process Inflammatory / Fibrotic Disease Chronic Inflammation / Fibrosis 2 2 2 2 2 2 | Activation Resolution iE | Activation c 4 2 Ss oS oS £ € £ £ a a = = Time Time Immune System Returns to Homeostasis Immune System is Unable t
Slide 10: Anabasum Promotes Resolution of Inflammation and Fibrotic Responses
~ Anabasum Promotes Resolution of Inflammation and Fibrotic Responses Resolution of Chronic Inflammation and Fibrosis aN Activation Inflammation / Fibrosis \ \ \ 1 1 \ \ N ‘=> Homeostasis Time MOA Applicable to Multiple Inflammatory / Fibrotic Diseases 10
Slide 11: Endocannabinoids Play a Unique Role in Inflammation and Fibrosis
x Endocannabinoids Play a Unique Role in Inflammation and Fibrosis MOA of CB2 agonism: triggers resolution of inflammation’ Resolution of Inflammation and Fibrosis Endocannabinoid System CORBUS 44 _1:shinohara 2012
Slide 12: The Endocannabinoid System Has a Dual Role
' The Endocannabinoid System Has a Dual Role ° Pain Central Nausea Nervous * Spasms System * Appetite CB1 receptorsare ‘mostly found in the brain Immune System ° Immune modulation CB2 receptorsare mostly within the immunesystem 12
Slide 13: Attractive Candidate for Rare Chronic Inflammatory / Fibrotic Diseases
x Attractive Candidate for Rare + Chronic Inflammatory / Fibrotic Diseases High ) Low ») Targeting >) ea mg — oo Inflammation Without *CB2 Binding Affinity °CB1 Binding Affinity Immunosuppression (Pro-resolution receptors in (Analgesic receptors in the mm: the immune system) brain) and Limited CNS *
Slide 14: Systemic Sclerosis
Slide 15: Systemic Sclerosis Key Takeaways
Systemic Sclerosis Chronic systemic autoimmune disease causing fibrosis of skin and internal organs Key Takeaways Life-threatening, rare disease ay No SSc-specific drugs approved Current therapy: Immunosuppressive agents (safety risk) Need for proven safe and effective therapies eG +EU heeeeeet (0)
Slide 16: Ongoing Phase 3 RESOLVE-1 Study
Ongoing Phase 3 RESOLVE-1 Study Topline data expected 2020 \ ~ 354 Subjects Multinational Double-blind i Ea ea | overall ratio of ¥ ae See anabasum:placebo randomized, placebo-controlled 52 week study & 20mg BID Kaa Primary Endpoint: Secondary Endpoints: * Change from baseline in mRSS * Change from
Slide 17: Ongoing Open-Label Extension - Significant Improvement in mRSS
and Other Clinical Outcomes at 28-Weeks x Ongoing Open-Label Extension - Significant Improvement in mRSS Open-Label Extension é 28 weeks active dosing C2 36 Adults =D 75% of subjects achieved degree : ; 33% reached 22% reached 8% reached of improvement ” mRSS < 10 (low mRSS <5 (very mRSS = 0 Mixee e
Slide 18: mRSS Results from Phase 2 Study
y mRSS Results from Phase 2 Study — Primary Outcome for Phase 3 RESOLVE-1 Study Achieved reduction in mRSS of 8.4 points from start of study (p < 0.0001, 2-side paired t-test) exceeding clinically important improvement (-4.7 points) Double-Blinded Dosing Off Treatment Open-Label Dosing 25 w Bs ® 38
Slide 19: ACR CRISS Results from Phase 2 Study
% ACR CRISS Results from Phase 2 Study ACR CRISS reached 71% (median) from start of study with 44% of subjects achieving a score > 70% Double-Blinded Dosing Off Treatment Open-Label Dosing 08 o7 71% 06 59% 06 04 45% 03 35% 28% 02 Median ACR CRISS Score 19% 04 3% 2% 1% 0% Day1 Week 4 Week8 Week 12 ©
Slide 20: Safety and Tolerability Summary from Phase 2 Study
x Safety and Tolerability Summary from Phase 2 Study « Anabasum was well tolerated « No serious or severe anabasum-related TEAEs noted - Most common adverse events were mild/moderate: - Dizziness (22% in anabasum-treated subjects vs. 13% in placebo-treated subjects) - Fatigue (19% in anabasum-treate
Slide 21: Cystic Fibrosis
® 2 ‘ to comm - Support from the Cystic Fibrosis Foundation
Slide 22: Cystic Fibrosis Key Takeaways
Cystic Fibrosis Key Takeaways CF is a life-threatening, genetic disease that primarily affects the lungs and digestive system. CF is characterized by chronic lung inflammation that leads to lung damage and fibrosis. Life-threatening, rare disease Inflammation and fibrosis play key role in CF morbidi
Slide 23: Pulmonary Exacerbations (PEx)
PEx PULMONARY Cost EXACERBATIONS . . $95,000 Dangerous manifestation per enicode of lung disease Shortness Annual rate yA M of breath, cough, sputum production and reduced FEV1 Increased ( )) inflammation accompanies PEx Irreversible lung function loss, including FEV1 CORBUS sss Multiple ne PEx per
Slide 24: Design of Completed Phase 2 Study
24 Design of Completed Phase 2 Study Positive Data Announced March 2017 85 Adults 21 clinical sites across Double-blind the U. 5. and Europe 7 “ randomized, placebo-controlled 16 week study — 12 week active dosing > 1mgap Jag 20 mg QD alg &, 4 fas) x 5mg QD eS x & 20 mg BID BT eleccto | Secondary En
Slide 25: Safety and Tolerability Summary
x Safety and Tolerability Summary « Anabasum was well tolerated - No serious or severe anabasum-related TEAEs noted * Most common anabasum-related mild adverse event: - Dry mouth (mild, 13% vs 0% in placebo) ° FEV-1 remained stable throughout the study across all cohorts CORBUSY OB _____.. rrrrrrrrr
Slide 26: Anabasum Increases Time to First New Pulmonary Exacerbations
- Anabasum Increases Time to First New Pulmonary Exacerbations Treated with Oral or IV Antibiotics - - . a Rate of Pulmonary Exacerbations aa Kaplan-Meier Survival Time Without a PEx is ry as Requiring IV Antibiotics te * Censored J Weeks 1-4 Weeks 5-12 i Anabasum 03 03 2 2 = g a S 025 0.25 B 06 8 £
Slide 27: Consistent Reduction in Key Inflammatory Biomarkers (Sputum)
' Consistent Reduction in Key Inflammatory Biomarkers (Sputum) Reduction with anabasum 20 mg BID compared to placebo (Log,)) Neutrophils, cells/ml p= 0.053-—_______{ Eosinophils, cells/ml p= 0.089 Lymphocytes, cells/ml Macrophages, cells/ml 3 | Neutrophil elastase, cells/ml IL-8, pg/ml IgG, mg/dl 25
Slide 28: Next Steps
ext Steps Discussions with the Cystic Fibrosis Foundation 28
Slide 29: Dermatomyositis
Dermatomyositis: - Positive Phase 2 data - Late-breaking data presented at ACR - Ongoing open-label extension - Next clinical study expected to commence H2 2018 CORBUS ¥ PHARMACEUTICALS 29
Slide 30: Dermatomyositis Key Takeaways
30 Dermatomyositis Key Takeaways Chronic systemic autoimmune disease characterized by inflammation of skin and muscles ee U.S. + EU Pheri Skin & Muscle w-N Involvement can cause significant morbidity yy and mortality from interstitial lung disease No FDA NIH) Approved therapies for overall disease a
Slide 31: Dermatomyositis Phase 2 Clinical Study
x Dermatomyositis Phase 2 Clinical Study Positive Data Announced November 2017 22 Adults 1 Site _. University of Pennsylvania Double-blind Perelman School of Medicine eeitttit randomized, placebo-controlled at » Y. nets Sys es 9 1:1 overall ratio of Hog & or g or x Oo Primary Endpoints: Secondary En
Slide 32: Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
y Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) CDASI was developed to measure multiple inflammatory elements in the skin‘ Disease Severity Measurement Location SCALP PERIORBITAL MALAR AREA REST OF THE FACE | i 48 POSTERIOR NECK V-AREA NECK (FRONTAL) UPPER BACK & SHOULDERS ARM RE
Slide 33: CDASI Score - Anabasum Demonstrated Clinically Meaningful Improvement
y CDASI Score — Anabasum Demonstrated Clinically Meaningful Improvement Anabasum improved CDASI by 9.3 vs. 3.7 for placebo; p = 0.04, 2-sided MMRM Clinically 6 meaningful improvement Improvement P=0.21 Mean Change from Day 1 (SE) =@-Anabasum -e-Placebo 4 6 8 10 12 14 16 Weeks Completed 20mg QD 20mg
Slide 34: Changes in Skin
x Changes in Skin SX 34
Slide 35: Safety and Tolerability Summary
x Safety and Tolerability Summary « Anabasum was well tolerated and demonstrated a favorable safety profile « No evidence of immunosuppression - No serious or severe side effects related to anabasum « No subjects dropped out of the study CORBUSY 5... rrr
Slide 36: Strong Evidence of Clinical Benefit Merits Further Development in Dermatomyositis
\v Strong Evidence of Clinical Benefit Merits Further Development in Dermatomyositis Meet with FDA CORBUSY 36
Slide 37: Systemic Lupus Erythematosus
Systemic Lupus Erythematosus: - Ongoing Phase 2 study - Funded by NIH NIAID Autoimmunity Centers of Excellence CORBUS ¥ PHARMACEUTICALS 37
Slide 38: Systemic Lupus Erythematosus Key Takeaways
38 Systemic Lupus Key Takeaways Erythematosus Chronic systemic autoimmune disease characterized by inflammation of skin and muscles /\ 500,000 wy af Patients in the US + EU FhTT + Occurs more often in women of child bearing age * Higher incidence and more severe in black andAsian populations NON-IMM
Slide 39: Ongoing SLE Phase 2 Study
x Ongoing SLE Phase 2 Study { Study Commenced December 2017 active musculoskeletal disease United states ~100 aduitste patients with 1 5 clinical sitesiinthe Double-blind Lay randomized, placebo-controlled PTATETETA TATA TET ETE PRRTETERETE TE TE TE TE TATE 1 - “4 overall ratio of anabasum:placebo &
Slide 40: Management Team
Management Team Yuval Cohen, PhD Chief Executive Officer, Director Co-founder and former President of Celsus Therapeutics (CLTX). Expertise in developing anti-inflammatory drugs including for CF Sean Moran, CPA, MBA Chief Financial Officer Former CFO: InVivo (NVIV), Celsion (CLSN), Transport Pharma,
Slide 41: Board of Directors
Board of Directors | ” Amb. Alan Holmer Ret. Chairman of the Board "YP Renucupta, MD fed = Former CEO of PhRMA (1996-2005) = Over 25 years of R&D, regulatory and senior management = Over two decades of public service in Washington, D.C. experience in the biopharma industry including Special Envoy to
Slide 42: Scientific Advisory and Principal Investigators
4 Scientific Advisory and Principal Investigators Scientific Advisors Principal Investigators ‘THE UNIVERSITY of NORTH CAROLINA at CHAPEL MILL. Michael Knowles, MD mi HARVARD MEDICAL SCHOOL Charles Serhan, PhD Robert Spiera, MD US PI -SSc a HOSPITAL FOR i SPECIAL SURGERY Christopher Denton, PhD, FRC
Slide 43: Expected Milestones
SSc: * Dose first patient in Phase 3 RESOLVE-1 study * Report data from OLE CF: * Commence Phase 2b study * Dose first patient in Phase 2b study DM: * Launch next study * Report data from OLE SLE: * Dose first patient in Phase 2 study 43 4 sss... Expected Milestones SSc: * Complete dosing in Phase 3
Slide 44: Financial Profile: CRBP (NASDAQ)
x Financial Profile: CRBP (NASDAQ) $120MM 55.6MM Raised to-date 81 6K $67 2MM $473 M M Common shares 50 day average + $20MM daily volume" Cash balance** non-dilutive funding from NIH. and CF Foundation Market cap* outstanding (64.6MM fully diluted)** ice of $8.50per share
Slide 45: Focused on rare diseases with no current approved therapies
Focused on rare diseases with no current approved therapies First-in-class drug targeting inflammation + fibrosis Multiple clinical and regulatory milestones expected in 2018 Building a commercial pharmaceutical company
Slide 46: Contact Us
x CONTACT US Corbus Pharmaceuticals Holdings, Inc. 617.963.0100 info@corbuspharma.com www.corbuspharma.com 100 River Ridge Drive Norwood, MA 02062
Slide 47: SSc Backup Slides
SSc Backup Slides
Slide 48: Design of Completed Phase 2 Study
Design of Completed Phase 2 Study Positive Results of Double-blinded, Placebo-controlled Portion of Trial Reported in November 2016 © clinical sites Double-blind across the U.S. 43 Ad u Its a - ei? randomized, placebo-controlled 12: al L Fy ag week study — 12 week active dosing AnananaTaS overall ra
Slide 49: mRSS: Skin Thickening Improved
x mRSS: Skin Thickening Improved Primary Endpoint in Phase 3 RESOLVE-1 Study 4 mRSS Change from Baseline =—®— Anabasum —@®=— Placebo Change in mRSS, LS means +SE 0 4 8 12 16 Reduction = improvement
Slide 50: Improved Patient Reported Skin Symptoms
Improved Patient Reported Skin Symptoms SSc Skin Symptom Assessment 5-D Itch Questionnaire” = e & a u Sitch score, change from baseline P?=0.044 P=0.004 P? = 0.032 ° 4 a2 ° 4 2 SScSkin Questionnaire score, change from baseline —®— Anabasum —®—Placebo: Reduction = improvement * Greater improvement in
Slide 51: Additional Efficacy Outcomes Favor Anabasum
- Additional Efficacy Outcomes Favor Anabasum HAQ-DI FVC% Predicted MDGA PtGA Change from Baseline Change from Baseline Change from Baseline. Change from Baseline ‘Change in HAQ-DI, LS means #5 Change in mEVC, LS means SE Change in MDGA, LS means #SE Pi=0.08 P=0.006 P=0.006 P=003 ° 4 8 2 6 Week 8 We
Slide 52: Improvements in ACR-CRISS Scores
' Improvements in ACR-CRISS Scores Median ACR CRISS Score P1 = 0.044 m Anabasum (n=26) @ Placebo (n=15) x ov 2 i) o n nw ea m cs) Increase = improvement 0 52. 1: LOCK. 1 sidedmixed model using ranktransformed data 2: 25th percentile, 75th percertile MARMACEUTL sy
Slide 53: On Target Effect: Anabasum Reduces Inflammation in Skin
~ On Target Effect: Anabasum Reduces /nflammation in Skin (Histology Analysis) Change in inflammation after only 12 weeks of treatment Placebo Anabasum 38% P = 0.008 Fisher’ ttest no cere 48% AmRSS = -1.2 AmRSS = -5.1 HB Worsened Unchanged Improved 53
Slide 54: On Target Effect: Anabasum Reduces Fibrosis in Skin
Analysis) x On Target Effect: Anabasum Reduces Fibrosis in Skin (Histology Change in fibrosis after only 12 weeks of treatment Placebo Anabasum 15% P=0.049 A3% Fisher's exact test 39% two-sided 48% AmRSS = -1.8 AmRSS = -4.0 HB Worsened Unchanged Improved 54
Slide 55: DM Backup Slides
DM Backup Slides 55
Slide 56: Additional Efficacy Outcomes Favor Anabasum
- Additional Efficacy Outcomes Favor Anabasum Patient Skin Global Skindex-29 Symptoms g 2 g S05 2 : 00 i a 5 é H p=009 3 _@ePlacebo sad eStats —@=Anabasum P=0.03 o 4 Weeks Completed (Gomeao > 20me810 > Fon] Povalue= {sided MRM, anabasum vs. placebo, change fom end of Weck 4 o 4 a Weeks Completed (Go
Corbus Pharmaceuticals Holdings — Investor Presentation (January 2018) on 6ix